EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study

Giuseppe Plazzi, Geert Mayer, Ralf Bodenschatz, Enrica Bonanni, Alessandro Cicolin, Giacomo Della Marca, Pierluigi Dolso, Luigi Ferini Strambi, Raffaele Ferri, Peter Geisler, Svenja Happe, Anna Heidbreder und 21 weitere

Sleep Medicine · 2025

DOI: 10.1016/j.sleep.2025.02.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sleep Medicine, 2025. Verfasst von Giuseppe Plazzi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Azienda USL di Bologna Ospedale Bellaria, Via Altura 3, 40139 Bologna, Italy. Electronic address: giuseppe.plazzi@isnb.it. Hauptthemen laut MEDLINE: Narcolepsy, Piperidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Medicines Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Narcolepsy is a chronic sleep disorder characterized mainly by excessive daytime sleepiness (EDS) and cataplexy in the case of narcolepsy type 1 (NT1). Pitolisant is a histamine 3 receptor antagonist/inverse agonist that reduces EDS and cataplexy in patients with narcolepsy. METHODS: We performed a prospective 5-year follow-up, non-interventional study of adults with NT1 and NT2 receiving pitolisant. The primary objectives were to collect information on the long-term safety of pitolisant and analyze the utilization patterns of pitolisant. The secondary objectives were to assess clinical benefit, adherence, impact on patients' quality of life, disease burden, and patient satisfaction. We reported the results of an interim analysis after 42.6 months. RESULTS: The population comprised 370 patients (mean age, 40 ± 15 years; 51.4 % women; NT1, 71.4 %; NT2, 28.6 %); 364 received ≥1 dose of pitolisant. Data were available for 356 patients (97.8 %). Most patients (68.4 %) had ≥1 comorbidity (obesity [BMI≥30], 31.9 %; neuropsychiatric, 31 %; and cardiovascular, 22.8 %). Forty-eight patients (13.2 %) had received no prior narcoleptic treatment, while 98 (31 %) were taking a previous therapy, which was switched to pitolisant. Treatment was combined with pitolisant in 218 (69 %) patients. Pitolisant was discontinued by 131 patients (35.4 %), mainly for safety reasons (14.3 %), lack of response (8.7 %), and patient decision (7.6 %). Overall, 355 treatment-emergent adverse events (3 serious) were reported by 156 patients (42.9 % of safety population), with 218 possibly treatment-related (61.4 %) in 109 patients (29.9 %). Improvements were observed in EDS, cataplexy, and quality of life. CONCLUSIONS: Pitolisant was generally safe and well tolerated in patients with NT1 and NT2 and can be used in both types. Improvements were found in EDS, cataplexy, and quality of life, with good adherence and satisfaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NarcolepsyPiperidinesHumansMaleFemaleAdultProspective StudiesMiddle AgedQuality of LifeEuropePatient SatisfactionTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

EfficacyEuropeNarcolepsyPitolisantSafety

Substanzen

pitolisantPiperidines

Autor:innen und Institutionen

  • Azienda USL di Bologna Ospedale Bellaria, Via Altura 3, 40139 Bologna, Italy. Electronic address: giuseppe.plazzi@isnb.it.
  • Oberarzt-Leiter des Schalfzentrums, Hephata-Klinik Schimmelpfengstraße 6, Schwalmstadt-Treysa, 34613, Germany. Electronic address: geert.mayer@hephata.de.
  • Pharmakologisches Studienzentrum Chemnitz GmbH, Carolastraße 2, 09111, Chemnitz, Germany. Electronic address: ralf.bodenschatz.sz@mvz-mittweida.de.
  • Centro Del Sonno Azienda Ospedaliero-Universitaria Pisana: Neurologia, Via Roma 67, 56100, Pisa, Italy. Electronic address: e.bonanni@med.unipi.it.
  • Centro Medicina Del Sonno, Via Cherasco 15, 10126, Torino, Italy. Electronic address: alessandro.cicolin@unito.it.
  • Policlinico Gemelli, Largo Gemelli 8, 00168, Roma, Italy. Electronic address: giacomodellamarca@gmail.com.

Förderung

  • European Medicines Agency

Zitieren

APA

Plazzi, G., Mayer, G., Bodenschatz, R., Bonanni, E., Cicolin, A., Della Marca, G., Dolso, P., Strambi, L. F., Ferri, R., Geisler, P., Happe, S., Heidbreder, A., Herold, J., Kallweit, U., Leclair-Visonneau, L., Lederer, K., Liguori, C., Meurling, J., Parrino, L., …, & Dauvilliers, Y. (2025). Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study. Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.02.012

Vancouver

Plazzi G, Mayer G, Bodenschatz R, Bonanni E, Cicolin A, Della Marca G, et al. Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study. Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.02.012

BibTeX
@article{Plazzi2025,
  author = {Plazzi, Giuseppe and Mayer, Geert and Bodenschatz, Ralf and Bonanni, Enrica and Cicolin, Alessandro and Della Marca, Giacomo and Dolso, Pierluigi and Strambi, Luigi Ferini and Ferri, Raffaele and Geisler, Peter and Happe, Svenja and Heidbreder, Anna and Herold, Jürgen and Kallweit, Ulf and Leclair-Visonneau, Laurène and Lederer, Katharina and Liguori, Claudio and Meurling, Johan and Parrino, Liborio and Proserpio, Paola and Puligheddu, Monica and Quera Salva, Maria Antonia and Remi, Jan and Romigi, Andrea and Rupprecht, Sven and Savarese, Maria Antonietta and Schaff, Jean-Luc and Terzaghi, Michele and Winter, Yaroslav and Caussé, Christian and Collin, Irène and Lecomte, Isabelle and Dauvilliers, Yves},
  title = {Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study},
  journal = {Sleep Medicine},
  year = {2025},
  doi = {10.1016/j.sleep.2025.02.012}
}
Kostenlos starten →